The study, published in the journal CVIR Oncology, explored whether proton magnetic resonance spectroscopy, often abbreviated as 1H-MRS, could identify the key components of a TACE procedure in a laboratory setting. Unlike conventional MRI, which produces anatomical images based on water and fat signals, magnetic resonance spectroscopy reads the chemical composition of tissue. Every molecule containing hydrogen protons resonates at a slightly different frequency, measured in parts per million on a chemical shift scale, and the resulting spectrum acts like a molecular barcode. Clinicians already use this method to measure metabolites in the brain, where markers such as N-acetylaspartate and lactate help diagnose tumors, strokes, and metabolic disease. The Marburg team asked a bolder question: could the same technique pick out a chemotherapy drug and its delivery vehicles amid the dense chemical noise of liver tissue?

To find out, the researchers used a preclinical 7 Tesla MRI scanner, roughly double the field strength of most clinical machines, and performed two-dimensional single-voxel spectroscopy using a STEAM sequence. Each measurement sampled a tiny cube of tissue just five millimeters on each side, with an echo time of 27 milliseconds, a repetition time of 2500 milliseconds, and 128 phase-encoding steps acquired over about five and a half minutes. They tested three substances central to TACE: doxorubicin, the cytostatic drug; Embozene TANDEM drug-eluting beads, microscopic polymer spheres that soak up the drug and release it slowly inside the tumor; and Lipiodol, an oily iodinated contrast agent commonly mixed into the embolic mixture. Each substance was measured first in a clean in-vitro setup, then embedded in pieces of porcine liver to simulate the messy chemical environment of real tissue.

The results were strikingly clear for doxorubicin. The drug’s most prominent spectroscopic signal, produced jointly by a methoxy group and a cycloalkyl group on its molecular structure, appeared at 3.46 plus or minus 0.04 parts per million in solution and at 3.54 plus or minus 0.02 parts per million inside liver tissue, close to the theoretically calculated value of 3.77 parts per million. Crucially, this peak sits in a region of the spectrum that is largely free of signals from endogenous liver metabolites, meaning the drug’s fingerprint stands out against the biological background. When the researchers measured doxorubicin-loaded Embozene beads inside liver tissue, the drug signal remained clearly detectable, and the weak signals from the polymer beads themselves did not interfere with the measurement. In other words, the carrier vanished spectroscopically while the payload remained visible.

Lipiodol told a different story. The oily agent generated enormous signals, ranging from about 0.69 to 2.14 parts per million ex vivo, that dwarfed everything else in the spectrum, including the native lipid peaks of the liver itself. This overwhelming intensity completely swamped the underlying tissue signals, which cuts both ways. On one hand, it means Lipiodol is trivially easy to detect, and its distribution could in principle be mapped spectroscopically. On the other hand, any drug hidden beneath the Lipiodol signal becomes nearly impossible to measure without sophisticated spectral-fitting tools such as LCModel, which are currently designed for metabolites rather than drugs. The authors note that computed tomography already offers validated methods for quantifying Lipiodol deposition after TACE, so a spectroscopic alternative for that specific agent may be unnecessary.

Why does any of this matter? The distribution and duration of intratumoral drug presence after TACE almost certainly varies from patient to patient, and it is reasonable to assume that this variation influences treatment response. Yet no technique in clinical use today can assess drug presence or its spatial and temporal distribution inside the tumor. Researchers have relied on ex-vivo instrumental microanalysis of resected tissue, which captures a static snapshot but misses the actual metabolic processes unfolding at the treatment site. If spectroscopy could be repeated over time in the same patient, it would generate a local drug profile, revealing how long doxorubicin persists in the tumor and whether it spreads uniformly or pools unevenly. That information could support individually adapted TACE protocols, with treatment intervals and drug doses tailored to what the spectrum actually shows rather than what population averages suggest.

The study also addressed a subtle but important pharmacological question: metabolization. Doxorubicin is broken down in the body into several metabolites, most notably doxorubicinol, in which a carbonyl oxygen is hydroxylated, along with aglycones such as doxorubicinone and 7-deoxydoxorubicinone. These transformations have been extensively characterized with techniques like high-performance liquid chromatography and liquid chromatography with tandem mass spectrometry. The encouraging news for spectroscopy is that the signaling methoxy group remains unchanged in all known metabolites, so the measured spectrum should not shift as the drug is metabolized. The researchers also observed that the clinical doxorubicin preparation contained lactose monohydrate as a bulking agent, whose theoretical signal range overlaps the drug’s main peak, potentially amplifying the signal. That quirk hints the method might even extend to other powdered parenteral formulations that use similar excipients.

The authors are candid about the limitations of their setup. Signal strengths varied between measurements, likely due to temperature changes affecting molecular mobility and relaxation times, and to pH-dependent proton exchange in different chemical environments. In-vitro measurements benefit from clean, homogeneous conditions that produce sharp, well-defined peaks, while ex-vivo tissue introduces biological background noise from lipids, proteins, and endogenous metabolites, along with magnetic field inhomogeneities that broaden and distort signals. The 7 Tesla preclinical scanner, though powerful, is still weaker than dedicated nuclear magnetic resonance instruments, which partly explains small deviations between measured and calculated chemical shifts. And the leap from porcine liver in a dish to a living human patient is substantial: in vivo spectroscopy must contend with motion, breathing, and the constraints of clinical field strengths.

Still, the proof of concept lands at a moment of genuine momentum for interventional oncology. TACE is a mainstay therapy for hepatocellular carcinoma, cholangiocellular carcinoma, and certain liver metastases, tumors that are fed predominantly by arterial blood and are therefore ideal targets for transarterial delivery. The regional advantage of intra-arterial chemotherapy, amplified by embolization-induced slowing of blood flow, is well established pharmacologically, but it has never been observable at the level of the individual tumor in real time. If 1H-MRS can be validated in animal models and then in patients, it could become the first bedside tool for confirming that a chemotherapy dose actually landed where it was intended and for tracking how long it lingers. The authors caution that the quality of evaluation will depend on dedicated software tools that still need detailed analysis. But the core message is simple and potentially transformative: the drug’s voice, long drowned out by the noise of tissue, can now be heard, and listening to it may one day make liver cancer therapy a genuinely personalized procedure.

Subject of Research: Proton magnetic resonance spectroscopy for monitoring chemotherapeutic drug delivery after transarterial chemoembolization of liver tumors

Article Title: Feasibility of proton magnetic resonance spectroscopy for the assessment of chemotherapeutic drug delivery after TACE: a proof of concept

Article References: Godzinski, A., Jedelská, J., König, A. M., & Mahnken, A. H. (2025). Feasibility of proton magnetic resonance spectroscopy for the assessment of chemotherapeutic drug delivery after TACE: a proof of concept. CVIR Oncology, 1(1), Article 10. https://doi.org/10.1007/s44343-025-00010-6

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00010-6

Keywords: transarterial chemoembolization, proton magnetic resonance spectroscopy, doxorubicin, liver cancer, drug delivery, drug-eluting beads, Lipiodol, interventional radiology, hepatocellular carcinoma, therapy monitoring, MRI, chemotherapy

The initiative, called the Think Tank HCC Meeting (TTHM), was designed by a team led by Roberto Iezzi and colleagues at Fondazione Policlinico Universitario Gemelli IRCCS in Rome, together with experts from institutions across Europe and beyond. Before the congress, 80 of 127 registered participants completed a 61-question online survey covering demographics, hospital facilities, ablation practice, transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and combined treatment strategies. During the meeting itself, attendees voted anonymously through a live polling system while an expert panel, deliberately structured to simulate a multidisciplinary tumor board (MDTB), debated anonymized patient cases divided into early, intermediate, and advanced disease stages. Seventy-two, sixty-four, and seventy-eight participants voted in the three respective sessions, allowing the organizers to compare stated habits with decisions made under the pressure of a realistic clinical scenario.

The respondent pool skewed heavily toward experienced European radiologists. Roughly 82.5 percent were radiologists, of whom more than 91 percent were fully certified, and nearly 44 percent reported more than fifteen years of clinical experience. Almost 88 percent of the hospitals represented were in Europe, with nearly half of all respondents working in Italy, a detail that the authors themselves flag as a major limitation. Still, the infrastructure data were revealing: 72.5 percent of centers held a weekly multidisciplinary tumor board, 77.5 percent worked in or were networked with a transplant center, and 36.25 percent of hospitals had no access to radioembolization at all, a gap that inevitably shapes treatment choices regardless of what any algorithm recommends.

One of the most striking findings concerns thermal ablation, the recommended curative option for patients with tumors smaller than three centimeters who cannot undergo resection or transplantation. Microwave ablation has now overtaken radiofrequency ablation as the dominant technique, particularly for lesions up to four centimeters, reflecting its ability to reach higher temperatures faster and with less susceptibility to heat-sink effects near blood vessels. Yet the survey exposed a sobering quality gap: only about 36 percent of respondents systematically assessed the ablative margin, the rim of treated tissue surrounding the tumor that is widely recognized as a key predictor of local recurrence. Even more concerning, a quarter of respondents never used a multiprobe approach, and the same proportion performed ablations without any navigation system, suggesting that the technological tools available to guarantee complete tumor coverage are not being uniformly deployed.

For larger tumors, the panel showed a clear preference for combining ablation with transarterial embolization or chemoembolization rather than attempting a multiprobe ablation alone, with more than two-thirds of voters favoring the combined strategy. The technical logic is compelling: embolization can be performed in a single step alongside ablation, shortening procedural time and hospitalization, and the sequence matters. Most participants preferred to ablate first, because the hyperemic response induced by thermal injury increases drug uptake during subsequent chemoembolization, particularly in the peripheral zone of the ablation where sublethal heating may leave viable tumor cells. Post-ablation embolization also offers a safety net for patients at high risk of intraprocedural bleeding, such as those with low platelet counts or tumors in difficult locations. Cone-beam CT emerged as a pivotal adjunct in these combined procedures, improving lesion detection, identifying feeding vessels, and helping predict early treatment response.

In the intermediate-stage category, where TACE is the guideline-endorsed standard, the survey reproduced one of the field’s longest-running debates. In the pre-congress questionnaire, up to 40 percent of radiologists preferred drug-eluting bead TACE (DEB-TACE) while fewer than 20 percent favored the conventional lipiodol-based technique; during the live session, however, more than 50 percent switched their preference to conventional TACE. This inconsistency mirrors the literature itself: the PRECISION-V trial failed to demonstrate superiority of DEB-TACE over conventional TACE in overall survival, yet DEB-TACE is generally associated with lower toxicity and fewer complications. Interestingly, participants rated plain transarterial embolization as inferior to chemoembolization, even though a meta-analysis by Lawson and colleagues found comparable survival and complication rates between the two approaches, a perception the authors suggest reflects outdated habits rather than current evidence.

Perhaps the most actionable discrepancy involved balloon-occlusion microcatheters, devices that temporarily block outflow during chemoembolization to concentrate the therapeutic agent within the tumor. More than 72 percent of participants reported never using them, despite mounting evidence, including propensity-matched European multicenter analyses, that balloon-occluded TACE achieves higher complete response rates than conventional techniques. The authors argue that this represents a clear case where real-world practice lags behind the science. A similar pattern appeared with radioembolization: 36 percent of hospitals lacked access to it entirely, and although three randomized controlled trials in advanced-stage patients showed no overall survival advantage over systemic therapy, 64 percent of respondents still considered TARE more useful than systemic treatment, and many centers continue to use it in intermediate-stage patients, supported by retrospective data and by the DOSISPHERE-01 trial, which demonstrated that personalized dosimetry significantly improves response and survival compared with standard dosimetry.

The advanced-stage findings were equally revealing. BCLC guidelines recommend systemic therapy for patients with portal vein tumor thrombosis, extrahepatic spread, or declining performance status, and they do not endorse locoregional options. Yet more than half of the surveyed practitioners considered TACE feasible in these patients, a view echoed by the global BRIDGE observational study, which found that TACE is used as first-line treatment in nearly half of BCLC-C patients worldwide. The panel identified specific subgroups, such as patients with preserved liver function and peripheral tumor thrombus, so-called quasi-C patients, or those intolerant of systemic therapy, in whom degradable starch microsphere TACE, which delivers chemotherapy without ischemic injury to the compromised liver, may offer meaningful benefit. The authors caution, however, that the boundary between performance status 0 and 1 is often razor-thin, making stage classification itself a source of variability.

The overall picture that emerges is one of substantial, sometimes unjustified heterogeneity. Some deviations from the guidelines are backed by recent literature and reflect legitimate personalization, particularly as treatment migration across BCLC stages has become a de facto standard of care and multidisciplinary tumor boards increasingly override strict algorithmic allocation, in some published series with equal or superior survival outcomes. Other deviations, the authors argue, are simply outdated practices or misconceptions lacking scientific support, and clinical expertise alone should not justify divergence from evidence-based recommendations. They call for mandatory margin assessment using contrast-enhanced CT or cone-beam CT with margin-confirmation software, greater standardization of embolic agents, and continuous education to close the gap between what trials demonstrate and what physicians do.

The study’s limitations are acknowledged candidly: the sample was small, and the overwhelming European, largely Italian, composition means the results may reflect regional practice rather than a genuinely global picture. The authors also note that the reasons behind the observed heterogeneity, whether rooted in resource constraints, training traditions, or reimbursement structures, cannot be deduced from a questionnaire alone and deserve dedicated investigation at national and international meetings. Still, as a proof of concept, the Think Tank format demonstrates that live, tumor-board-style polling can surface the hidden variability of clinical practice in a way that retrospective database studies cannot. As long as each interventional radiologist follows an individual approach, the authors conclude, treatment results will remain inconsistent, complicating both patient care and the integration of locoregional procedures into universal oncological guidelines.

Subject of Research: Real-world practice of locoregional treatments for hepatocellular carcinoma compared with BCLC guideline recommendations

Article Title: Think tank on locoregional treatments in hepatocellular carcinoma: a snapshot of real-life practice

Article References: Iezzi, R., Contegiacomo, A., Posa, A., Scrofani, A. R., Rocco, B., Maresca, A., Bargellini, I., Bilhim, T., Crocetti, L., De Cobelli, F., Gasbarrini, A., Goldberg, S. N., Lucatelli, P., Muñoz, F. G., Pompili, M., & Filippiadis, D. (2025). Think tank on locoregional treatments in hepatocellular carcinoma: a snapshot of real-life practice. CVIR Oncology, 1(1), Article 15. https://doi.org/10.1007/s44343-025-00016-0

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00016-0

Keywords: hepatocellular carcinoma, interventional radiology, locoregional therapy, BCLC staging system, transarterial chemoembolization, radioembolization, microwave ablation, multidisciplinary tumor board, clinical practice guidelines, drug-eluting beads, ablative margin, liver cancer

The research team, led by Siobhan Lee and Christian Abel of the Department of Medical Imaging with Elliot Lee of the University of New England, took advantage of an unplanned natural experiment. In early November 2021, the locally available formulation of doxorubicin, the anthracycline antibiotic most commonly used in conventional TACE, changed from a dilute 2 mg/mL solution to a concentrated 25 mg/mL preparation. Before the switch, patients received the drug diluted in 25 mL of total emulsion volume; afterwards, the same drug arrived in just 2 mL. Because the change reflected pharmacy supply rather than a deliberate therapeutic strategy, the researchers could compare the two eras without the pressure of a formal trial, analysing 57 consecutive patients who underwent 106 cTACE procedures between September 2019 and February 2024.

The results were strikingly flat. Median overall survival was 788 days, or 25.6 months, in the low-concentration group, compared with 710 days, or 23.3 months, in the high-concentration group, a difference that fell well short of statistical significance with a log-rank p-value of 0.757. Tumour response, assessed with the modified RECIST and EASL criteria at three and six months, showed no meaningful divergence between the groups. Disease-free survival at one, two, and three years was similarly indistinguishable, although the one-year figure, 14.5 percent versus 29.4 percent favouring the high-concentration cohort, approached significance at p = 0.052, a trend the authors flag as worth watching in longer follow-up.

Safety data were equally reassuring for the concentrated formulation. Post-embolization syndrome, the constellation of fever, abdominal pain, and nausea that follows embolization in some patients, occurred in 7.3 percent of the low-concentration group and 5.9 percent of the high-concentration group, a non-significant difference. Other complications were actually numerically less frequent in the concentrated era, at 12.7 percent versus 5.9 percent, and mean hospital admission was essentially identical at 1.35 versus 1.27 days. Interestingly, patients who did develop post-embolization syndrome tended to have larger baseline tumours, with a mean maximal dimension of 52.7 mm versus 35.2 mm, and more often had multifocal disease, echoing prior literature that identifies tumour size as a major predictor of the syndrome.

What did predict survival, powerfully, was disease stage. In Cox proportional hazards regression adjusted for baseline characteristics, patients in Barcelona Clinic Liver Cancer stage B faced a 5.51-fold higher hazard of death compared with stage A, while stage C patients faced an 8.83-fold higher hazard. Mean survival fell from 1543 days in stage A to 817 days in stage B and just 440 days in stage C, a gradient so steep it dominated every other variable. Neither Child-Pugh liver function scores, ECOG performance status, tumour size, nor any treatment factor independently predicted survival once stage was accounted for.

The null result lands in the middle of a long-running and increasingly uncomfortable debate about whether chemotherapy contributes anything at all to transarterial embolization in liver cancer. A foundational 2003 systematic review by Llovet and Bruix found that chemoembolization improved survival over control arms, helping cement cTACE as standard therapy. But a 2011 Cochrane review found insufficient evidence that adding chemotherapy to embolization improved survival, noting low methodological quality and significant risk of bias across the randomised trials. More recently, two separate systematic reviews and meta-analyses of randomised controlled trials directly comparing TACE with bland transarterial embolization, which uses no chemotherapy at all, found no significant difference in overall survival, progression-free survival, or objective response rate. One of those analyses, by Wang and colleagues, went as far as recommending bland embolization on cost grounds, given similar or reduced adverse event rates.

The new study’s findings are, in that light, potentially supportive of a limited therapeutic role for chemotherapy agents in HCC embolization. If a more than twelvefold increase in doxorubicin concentration produces no measurable difference in survival, response, or toxicity, it becomes harder to argue that the drug itself is the engine of the treatment’s benefit. The authors note that the higher-concentration group actually received a higher total doxorubicin dose, a higher Lipiodol-to-doxorubicin ratio of 3.3 versus 1.3, and a smaller total emulsion volume, all differences significant at p < 0.001, yet outcomes did not budge. Lipiodol itself is not merely a carrier; it acts as an embolic agent, inducing tumour ischemia, and prior work has shown that homogeneous Lipiodol retention on post-treatment imaging correlates with better overall and progression-free survival, while higher Lipiodol doses have been linked to more complete tumour necrosis and more stable emulsions in laboratory studies.

The study also sits within the parallel debate over drug-eluting bead TACE, or DEB-TACE, which loads doxorubicin onto calibrated microspheres to standardise delivery and overcome the operator-dependent, freshly mixed emulsion that defines conventional TACE. Meta-analyses comparing the two approaches have produced a patchwork of findings: some report improved response rates with beads, one 2025 review found a small but significant survival advantage of roughly 3.5 months, and others find no difference at all, often with substantial heterogeneity and publication bias. The 2025 European Association for the Study of the Liver guidelines sidestep the controversy by recommending that cTACE and DEB-TACE be considered equivalent, and that bland TAE be considered an acceptable alternative to TACE altogether. Cost analyses suggest drug-eluting beads carry higher upfront expense but may offset this through shorter stays and less post-procedural pain, with one estimate of 2.4 versus 2.0 quality-adjusted life years favouring the beads.

Beyond the headline null result, the study quietly documents an evolution in clinical practice. The later, high-concentration cohort contained significantly more patients with advanced BCLC stage C disease, higher Child-Pugh scores suggesting more severe cirrhosis, and higher ECOG performance status scores, indicating that the centre was progressively offering cTACE to sicker, more comorbid patients. The authors suggest this reflects a deliberate broadening of the treatment population, but it introduces a real risk of selection bias: the modest numerical survival edge in the early group could simply reflect its healthier starting point. The early group also had significantly larger baseline tumours, with a mean maximum dimension of 43 mm versus 31 mm, which correlated with a lower one-year disease-free survival that approached significance.

The authors are candid about the limitations inherent in the retrospective, single-centre design. Documentation of treatment details improved markedly over the study period, and inadequate records accounted for over half of the 35 excluded patients, a factor that may actually improve future research. Time to tumour progression was not calculated because retrospective imaging data were too variable, prompting the authors to use disease-free survival as an umbrella measure instead. The sample size, particularly at later endpoints where only six patients in the high-concentration group reached three years, limits statistical power, and the entanglement of the doxorubicin formulation change with shifts in Lipiodol ratio and emulsion volume cannot be fully disentangled. Still, the core message is difficult to ignore: within the doses used here, where even the high-concentration protocol never exceeded 50 mg of doxorubicin, the concentration of chemotherapy delivered during cTACE appears to matter little for how long patients live, how well their tumours respond, or how they feel afterwards. As the field awaits larger, prospective, multicentre trials, the study adds weight to a provocative possibility that the embolic machinery of TACE, not its chemical cargo, may be doing the heavy lifting.

Subject of Research: Doxorubicin concentration in conventional transarterial chemoembolization for hepatocellular carcinoma

Article Title: High-concentration doxorubicin in cTACE: a retrospective cohort study of efficacy and safety

Article References: Lee, S., Lee, E., & Abel, C. (2025). High-concentration doxorubicin in cTACE: a retrospective cohort study of efficacy and safety. CVIR Oncology, 1(1), Article 19. https://doi.org/10.1007/s44343-025-00022-2

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00022-2

Keywords: hepatocellular carcinoma, transarterial chemoembolization, doxorubicin, Lipiodol, overall survival, post-embolization syndrome, BCLC stage, drug-eluting beads, liver cancer, interventional radiology, chemotherapy, retrospective cohort study